Free Access
| Issue |
Med Sci (Paris)
Volume 26, Number 11, Novembre 2010
|
|
|---|---|---|
| Page(s) | 911 - 914 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/20102611911 | |
| Published online | 15 November 2010 | |
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010 ; 362 : 2251-9. [Google Scholar]
- Kantarjian H, Shah NP, Hocchaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010 ; 362 : 2260-70. [Google Scholar]
- O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 ; 348 : 994-1004. [Google Scholar]
- Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009 ; 23 : 1054-61. [Google Scholar]
- Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 ; 354 : 2542-51. [Google Scholar]
- Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 ; 354 : 2531-41. [Google Scholar]
- Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009 ; 114 : 4933-8. [Google Scholar]
- Cortes JE, Jones D, O’Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010 ; 28 : 392-7. [Google Scholar]
- Cortes JE, Jones D, O’Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010 ; 28 : 398-404. [Google Scholar]
- Turhan A. Imatinib mesylate: a major breakthrough in the treatment of chronic myelogenous leukemia. Med Sci (Paris) 2003 ; 19 : 667-8 [Google Scholar]
- Roche-Lestienne C, Mahon FX, Preudhomme C. Origin of resistance to Imatinib mesylate: lessons learned from this experience. Med Sci (Paris) 2004 ; 20 : 1125-30 [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.